Henovcom Bioscience
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An antibody-focused biotech developing immunomodulatory therapies for oncology and immunology.
OncologyImmunology
Technology Platform
A proprietary antibody discovery and engineering platform focused on generating high-affinity, humanized antibodies against immunology targets.
Opportunities
Potential to demonstrate best-in-class efficacy or safety in early trials, leading to a lucrative partnership or acquisition.
Risk Factors
Clinical failure of its lead candidate could significantly diminish company value and access to capital.
Competitive Landscape
Navigates a highly competitive field with many companies pursuing similar immune-oncology and immunology targets.